Financial News

Financial Report: Novartis

Innovative Medicines sales up 2% in the quarter, partially offset by generic competition for Gleevec

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Novartis 3Q Revenues: $12.4 billion (+2%) 3Q Earnings: $2.1 billion (+7%) YTD Revenues: $36.2 billion (flat)   YTD Earnings: $5.7 billion (-1%) Comments: Innovative Medicines sales were $8.3 billion, up 2% in the quarter. Volume contributed 8 percentage points to sales growth. Generic competition had a negative impact of 6 percentage points largely due to Gleevec/Glivec generics in Europe and the U.S. Growth in the quarter was driven by Cosentyx ($556 million, +83% cc), Entresto ($128 milli...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters